A Pilot Study Targeting Angiogenesis Using Bevacizumab Combined With Chemotherapy and Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 07 Feb 2017
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel (Primary) ; Gemcitabine (Primary) ; Valproic acid (Primary)
- Indications Sarcoma
- Focus Adverse reactions
- 02 Feb 2017 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.
- 10 May 2016 Status changed from recruiting to active, no longer recruiting.
- 22 Jun 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Jul 2016, according to to ClinicalTrials.gov record.